Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.

Date publication

juin 2022

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine

Tous les auteurs :
Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, Connell RO, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35718565

Résumé

The Measure of Ovarian Symptoms and Treatment (MOST) concerns is a validated patient-reported symptom assessment tool for assessing symptom benefit and adverse effects of palliative chemotherapy in women with recurrent ovarian cancer (ROC). We aimed to examine (i) how symptoms within MOST symptom indexes track together (i.e. co-occur) and (ii) the association between MOST symptom indexes and key aspects of health-related quality of life (HRQL).

Mots clés

Health-related quality of life, Patient reported outcomes, Recurrent ovarian cancer, Symptom management

Référence

Gynecol Oncol. 2022 06 16;: